发明公开
EP2802589A1 FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS
有权
ANNE内衬吡咯AS IP受体激动剂治疗肺动脉高压（PAH）PAH及相关疾病
- 专利标题： FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS
- 专利标题（中）： ANNE内衬吡咯AS IP受体激动剂治疗肺动脉高压（PAH）PAH及相关疾病
-
申请号： EP13705578.6申请日： 2013-01-11
-
公开(公告)号： EP2802589A1公开(公告)日： 2014-11-19
- 发明人: LEBLANC, Catherine , ADCOCK, Claire
- 申请人： Novartis AG
- 申请人地址： Lichtstrasse 35 4056 Basel CH
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： Lichtstrasse 35 4056 Basel CH
- 代理机构： Hodge, Emma Jane
- 优先权： US201261586546P 20120113
- 国际公布： WO2013105057 20130718
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61K31/4985 ; A61P9/00 ; A61P11/00
摘要：
The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Formula (1a) (1b)
公开/授权文献
信息查询
